IM Cannabis (IMCC) - Long-Term Debt to Capital

IMC - graphic logo of issuer IMCC

IM Cannabis Corp. (IMCC) management has redirected sales toward the growing markets of Israel and Germany. The debt-to-equity ratio reflects the results of this strategy, where 0.00 records a new level. The business relies on premium brands and pharmacy chains, scaling production through high-tech greenhouses to reduce costs and increase overall profitability.

imcannabis.com (IMCC) - Long-Term Debt to Capital from 07/04/2022 to 10/30/2026

Analytical breakdowns for IM Cannabis Corp (IMCC)

- current price and projected stock value:
Share Price IMC|IMCC - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization IM Cannabis Corp.|IMCC - Total Company Value
- company book value details:
Accounting Value of a Share IM Cannabis|IMCC - Book Capitalization|Market Cap to Net Assets Ratio imcannabis.com|IMCC - Aggregate Company Assets
- company liabilities and liquidity data:
Debt to Capital IM Cannabis Corp.|IMCC - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital IMC|IMCC - Company Aggregate Debts|Debts to Book Capitalization Ratio IM Cannabis Corp.|IMCC - Company Long-Term Debts|Company Short-Term Debts IM Cannabis|Intermediate Coverage Ratio imcannabis.com
- earnings and valuation multiples indicators:
IMCC - Company Net Income
Summary company analysis:imcannabis.com (IMCC)
Original product of IM Cannabis Corp.

Investors are seeking fundamental stability by analyzing the liability structure. This ratio compares the volume of loans with maturities exceeding one year against equity to determine the degree of financial leverage. For IM Cannabis Corp. (IMCC), this balance is critical during its expansion into Germany and Israel. Controlling the debt load mitigates the region's geopolitical risks. Evaluate the long-term debt-to-equity dynamics to understand the margin of safety.

Key competitors

Long-Term Debt to Capital Ratio INDV (Indivior plc)|Long-Term Debt to Capital COLL|Long-Term Debt to Capital Cronos Corp (CRON)|Long-Term Debt to Equity Canopy Growth CGC|Long-Term Debt to Capital Coefficient HITI|Aurora - Long-Term Debt to Capital|Achieve Life Sciences Inc. (ACHV) - Long-Term Debt to Equity Ratio|Skye Bioscience, Inc. (SKYE) - Long-Term Debt to Equity|Long-Term Liabilities to Capital Anebulo Pharma (ANEB)|Long-Term Debt to Equity Ratio INCR|NTRB: Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital NSRX|IGC: Long-Term Liabilities to Equity|Long-Term Debt to Capital MIRA (MIRA Pharmaceuticals, Inc.)|Long-Term Debt to Capital Flora Growth Inc FLGC|ADIL - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient ARTL (Artelo Biosciences)|ensysce.com (ENSC) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Titan Pharmaceuticals, Inc.|GNLN (Greenlane Holdings Inc) - Long-Term Debt to Capital|InMed (INM) - Ratio of Long-Term Indebtedness to Capital|Long-Term Debt to Equity Akanda (AKAN)|Long-Term Debt to Equity Ratio enveric.com ENVB|Bright Green Corporation - Long-Term Debt to Equity Ratio|Long-Term Debt to Capital Coefficient HPCO